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I NrRODUCTION

The object of this paper is to review the literature pertaining to the ne chanism of' action o'f the ar-s enioal preparations
now being used in the treatment of syphilis with the idea in
mirxl o'f attempting to evaluate the eff ectiveness o~ the oom:pounds with reference to their therapeutic uses.

This seems to

be a timely subject in view of' the fact that with the present
war tine conditions the incidence of syphilis is al nost certainly
bound to increase in spite of public health attempts at its
control.

With this inevitable increase in the incidence of

early syphilis, primarily the problem of' adequate therapy becomes more and more inportant.

Recently new drugs have been

added to the armamentar1um of' the syph1lologists, in particular
mapharsen, and with the introduction of this drug, modern
syphilologists have again begun to think of Ehrlichs dream of
"therapia sterilisans magna" in the form o'f continuous intravenous nedication for a 'few days and massive intravenous injections over a ten day period in the treatment of syphilis
particularly the primary and secorxlary stages.

This principle

of one sterilizing course of treatment would naturally be of
inestimable value since the present day mode of' therapy is
definitely too long a process f'or adequate management of all
cases.

In short, it can be said the present 'form of' treatment
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is too long, too pairt'ul, too dangerous,

am too expensive.

Our present system o~ antisyphilitic treatment has much to be
asked for in the proper control of syphilis.
Naturally, any therapeutic agent must be evaluated both
cli~cally and experimentally to determine its effectiveness,
and far better insight into a disease process and means for
its control oan be obtained if the clinician understands the
mechanism whereby his drugs exert their effeot rather than
using them empirically.

It is with this purpose in mind

that the following pages have been written, i.e. to review
the literature with the intent of reaching some conclusion
regarding the mechanism of action of the arseniaals and a
rationale for their use in the treatment of syphilis.

With

this kmwledge of the mechanism of action we can then perhaps
better evaluate the present day therape utic nethode which are
being used, especially in the treatment of early syphili~ and
it is in early syphilis that we stand our best chance of
eradicating syphilis both from the publ i c health standpoint
and ·-rrom the late ravages to the individual victim.

&
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HISTORY
A history o~ the development of the arsen1cal preparations
used in the therapy of syphilis is almost a history o~ syphilis.
Ever since the clinical recognition of syphilis man has sought
after means for combating this dread disease.

The origin of

syphilis is still problematical and only of academic interest
in the first place; although, the disease was apparently not
recognized in Europe until after the discovery of the New World
which has led historians to presume that syphilis was introduced to Europe by the sailors of Columbus and other explorers
who contracted the disease in American and brought it home to
Europe whence it spread like wild fire,until at present, it is
known among all peoples of the world.
Although syphilis was recognized as disease entity in
Europe for a long time, 1t is of interest to note that there
was little or no progress in the development of therapy
following its introduction to Europe for over three hundred
years.

It is somewhat paradoxical to note that while amazingly

good clinical observations and descriptions of the disease
were IJBde by many workers ever since the discovery of the disease, literally no progress was made in the treatment of the
disease.

The treatment which was use.d in past centuries also

seems somewhat unjustified to Kemp (1) since, in spite of the
treatments used, no clinical arrests of the disease were made.
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However, it must be remembered that during these times no
laboratory procedures were available to check upon the
ef~icaey of different preparations such as we have today in
the form o~ dark-field examinations and sensitive serological
tests.
Alaey preparations (1) were used in the treatment of

syphilis and among these might be listed guaicum, China root,
sarsaparilla, and sassafras, all of which enjoyed their respective periods of popularity.

It was not, however, until

approximately 1600 that any antisyphilitio agent of therapeutic
potency as we see it today was introduced.

Paracelsus in 1568

is usually credited with the introduction of mercury as an
antisyphilitic agent • . It is unfortunate that the advent of
mercury should meet with so ~ny disastrous reactions due to
its misuse.

Following its introduction (1) many cases of

hemorrhagic gastroenteritis and :nephritis were noted in patients
being treated with the drug. · These reaotions were so seriou
at one time that medical students of He1dleberg were required
to take an oath, from 1580 to 1655, to the effect that they
would, at no time, use mercury in the treatment of syphilis.
The next drug of valuable therapeutic power to be introduced
was potassium iodide, which is supposed to have been introduced
by Wallace in 1835.
Following ~he introduction of mercury and potassium iodide
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to the armamentarium

or

the syphilologist, little or no

'

progress was made in the treatment Of syphilis until the
turn o~ the present century and the momentous work
Ehrlich and his contemporaries-with one exception.

or
In

1887, Von Jauregg (1) noted that there was o~ten an improvement in cases of general paresis following an acute febrile
attack, and in 1917 he used malarial fever therapy (tertian)

in the treatment o~ paresis and this therapy was admitted o~
good therapeutic ef~iciency.

Since then, it has been in

vogue until the advent of modern artificial hyperpyrexia
cabinets, et cetera.
With the turn of the present century and the discovery
of the Treponema pallid& as the etiologic_al agent or syphilis
by Sohaudin . in 1906, and the development o~ serological
diagnostic tests by Bordet, Wassermann, and subsequent workers
the field was 1meed ripe for some concrete advances in the
therapy of syphilis.

It had long been kmwn that arsenic at

times produced certain e"f"feots in syphilis (2), but the
results were unreliable and consequently arsenic had never
played any great part in the therapy of syphilis.

Occasionally

however, it had been used in those cases which were resistant
to mercury therapy.

It was the experimental work of Uhlenhuth,

Gross, and Bickel in 1907 with atoxyl in experimental hen
spir1llos1s which precipitated all the ~urther work o~ Ehrlich
and his colleagues.

The hen sp1r1llosis (Sp. gallinarum) was
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•
found to be favorably treated with atoxyl by these workers
and they found that doses (single) of 0.05 gm.per kilo. were
both curative and prophylaotioally sound.

Naturally, this

suggested the use of' atoxyl in the treatment of syphilis
which had recently been shown to be a spirochetal disease.
However, treatment of' syphilis with organic arsenieal preparations including atoxyl was soon abandoned because of" the
detrimental eff'ects to the host, especially to the optic
nerve.
At this time Ehrlich attacked the problem from the viewpoint of determining the mechanism whereby the ohemotherapeutio
agents killed the parasites.

He also advanced his "tropism"

theory as explained later in this paper and began a series of
investigations into the organotropic and .Parasititropio ef'feots
of many organic arsenical compounds.

He first employed atoxyl

(2) and with the assistance of Bertheim showed it to be a
sodium salt of' paraminophenyl acid, a very stable .and at the
same tine strongly reacting substance. · By transforming and
attacking the amido group Ehrlich sucneded in obtaining an
infinite variety of' compounds, all of" which oonta1Md the
radical of an organically fixed arsenic acid.

Out of" hundreds

of' substances experimented with on animals, only a f'ew were
. founi to be available particularly arsaoet1n, arsenophenylglyoin, and salvarsan.

Salvarsan or arsphenam1ne was pre-

pared by Dr. Bertheim in Ebrlichs laboratory and the animal
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experimentation was done by Hata.

When the therapeutic

potency of salvarsan had been determined by them; and when
they had noticed the lack of gross toxicity in experimental
rabbit syphilis, Ehrlich sent the preparation o~ Professor
Alt at Uchtpringe, Germany (4) for ~nvestigation o~ its toxic
and therapeutic properties as related to men.

After a number

of investigations upon dogs with reference to toxicity, two
physicians permitted themselves to be injected with salvarean
and they experienoed nothing but pain and swelling at the
site of injection with no untoward after e~fects whatsoever.
From here on Alt performed his work upon paralytics and noted
that while pain was severe at the point of intramuscular injection and there was a temporary rise in temperature to
about 102° F. neither infiltration or abscesses were noted
and the patients

showed rather marked clinical improvement

and reversal of the Wassermann reaction in a large percentage ·
of oases.

Salvarsan was originally given intramuscularly

because it was believed that its therapeutic effect was enhanced because o~ delayed elimination.

These experimente and

clinical trials of Pro~essor Alts were accomplished in 1909,
and in 1910 the drug was placed on the market as salvarsan, eo
named because it was believed that the preparation would be
the salvation o~ mankind.
Ehrlich's aim had been to produce an antisyphilitio agent
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of" such potency that would kill every spirochaete in the
body and thus realize his dream o~ 'therapia sterilsans . magna".
As a result o~ this aim o~ Ehrlich's many syphilitics were
grossly undertreated with disasterous late results.

In 1911

( 4 ) the intravenous method of" treatment was adopted and
Ehrlich's "therapia ster111sane magna" became only a cherished
dream.

Arsphenamine and neoarsphenamine were introduced to

the syphilologists armamentarium from 1910 to 1911 and 1n ·.rapid
'

suooession since that time until the present several antisyphilitic agents of high therapeutic ef~iciency have been
introduced, namely; silver arsphenamine in 1918, tryparsam1d.e
and sulpharsphenarn1ne 1n 1919, stovarsol in 1921, and mapharsen
in 1934.

It is o~ interest to note that all of these prepara-

tions except silver arsphenamine and sulpharsphenamine were
studied by Ehrlich but were discarded because of" real or'
supposed toxicity.
The next big advance in the chemotherapy of syphilis was
made by Sazerao an:l Leviditii in 1921 (1) with -the introduction of bismuth compounds to the list of antisyphilitic
agents.
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MECHANISM OF ACTI ON OF ANTISYPHILITIC ARSENIOAL
COMPOUNDS
Kolmer (3) summarizes the possible mechanisms by which
chemotherapeutic agents exert their parsiticidal action in
the hunan body by listing the following possibilities:
1.

A direet chemical interaction between the compound

or drug administered, or after some transformation of' the
compo~d within the body, with some protoplasmic constituent
of the parasite resulting in the death or crippling of the
parasite by interference with its vital processes of internal
I

respiration;
2.

piys1oo-chemical interaction between the compound and

and the protoplasmic colloids of the parasite involving pre•
oipitation, coagulation, and changes in electrical charge
sufficient for destruction of the parasite;
3.

production of new compounds in tiss ues capable of'

cheml.oal or physico chemical protoplasmic action on parasites
producing effects different from those of the original
compound;
~-

production of antibodies by releasing antigenic

substance from the parasites;
5.

stimulation of oxidation, production of hyperemia,

stimulation of rep':ll"ative processes, produ~t1on of leukooytosis
phagocytosis, and mobilization o~ proteolytic and lipolytic
enzymes capable of cri9pling parasites.
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With these ~ive possible means whereby the chemotherapeutic agents may exert their action it is the purpose
of this section to critically review and discuss the

literature with the purpose in mind o~ trying to arrive at
son»3 conclusion as to the nature of action ot the organic
arsenioal ooupounds used in the treatment of syphilis.

It

appears to the author that such a review is especially timely
in view of the modern introduction of new drugs as mapharsen
into the treatment of syphilis and the new intensive massive
dose therapy and continuous intravenous therapy.

Since all

chenotherapeutic agents must be less toxic to the host than
to the parasite in order to be of any therapeutic value, it
seems that a thorough and critical analysis o~ the pharmacological actions o~ these drugs is needed especially as pertains to their mechanism of action upon the parasites, since
unless the drugs can be shown to have relatively qµick action
upon the parasites theIIBelves, the massive continuous form of
therapy is not reasonable.
Ehrlich (5) postulated the "parasitotropic" and
"organotropic" views of chemotherapy early in the present
century when he stated that the mechanism whereby parasites
were killed by chemotherapeutic agents was such that these
agents became fixed to the parasites thereby killing them.
He also stated that the cells of the iniividual being treated
with these agents were capable of having the drug fixed to
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them.

This action between drug and parsite was the

"parasitotropio" action o-r the drug and that between drug
and body cell was the •organotropio" action of the drug.
Ehrlich was fully conscio\_ls ·· o'f the

fact that a proper

balance between these two actions was essential before
success oould be attained with any ohemotherapeutio agent.
Ehrlich was also aware o-r the faot that there were exceptions
to this rule, but he used it as a guiding principle in his
work.

Ehrlich believed that living cells had

11

chemorecepto~s"

of a similar nature to those which he postula~es in his
famous antigen-antibody side chain theory of immunity.

He

believed that these chemorecepto~s were specific for certain
drugs as evidenced by his experiments which have shown that
aninels may be drug fast to a certain preparation so that this
preparation has no therapeutic effect after nun:erous small
doses o'f' the preparation, but after becoming drug fast the
therapeutic effect of a similar drug is at once evidenced
with its administration.
As further evidence for the principle o-r fixation Ehrlich
cites the work of Hata (5) who first showed that parasites
when m1.xed alone with salvarsan did not reduce their motility.
However, when the treated parasites were injected into
Jabo~atory ani~als these animals showed no signs of infection,
whlch h e believed cast out the theory of antibody stimulation
as the mechanism of salvarasan action and also served as
evidence for linkage of drug to parasite.
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Lee (6) has an interesting idea as to the mechanism of'
action of' the organic arsenioal antisyphilitic agents.

He

states that the Treponema derives its nourishment from tissue
cellular protein, and that arsen1oal drugs as they pass
through the capillary system in a fine orystalloid state
pass through the endothelial membranes by diffusion and
osmsis.

The arsenobenzol group, the group of greatest

affirt.ty, attaches itself' to the cell ular protein, producing
an arsenoprote1 n substance which is not only an unfavorable
culture nedium for the parasite, but is directly poisonous
to the parasite.

Lee cites two facts a s evidence for this

· theory, one clinical and one experimental.

Clinically he

states an area of' redness is of'ten seen around a syphilitic
lesion twenty-four to forty-eight hours after treatment and
the patient will of'ten complain of' heat, pain, and tenderness
in these areas.

Experimentally he states that excised syph-

ilitic tissue is spiroche t 1cidal in vitro af'ter treatment
with arsphenamines as further evidence in support of' his
theory as well as the f a ct that Noguchi has shown that fresh
tissue from an animal to which the tre ponema is adapted is
necessary for cultivation of the organism.
MoDonagh in 1917 (7) advanced a t h eory concerning the
chem:>therapy of syphilis which 1s of only passing interest
in view of mre mdern concepts of the treatment of the disease.
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He observed the rioe in central nervous system syphilis
following what was at the tine believed to be adequate
therapy consisting o~ eleven intravemus salvarsan injections
followed by eleven intramuscular bismuth or nercury injections
and pron~uncement of cure.

He blamed these recurrences upon

the use o~ arsenic compounds and coniemmed their use at this
time.

He believed that the coabined use of oxidizing and

reducing agents was ouch better than the use of one alone.
postulated

He

that salvarsan does not attack the parasites

directly, but only indirectly by increasing the o~1d1z1ng
action of protein particles in serum and in plasma cells.
'

Metals are in general oxidizing agents and non-metals reducing.
He stated that the chem:>therapeut1c agents are m::>re potent
in protozoal diseases and especially syphilis, because of
the inoreas~d size and number of protein particles circulating
in serum, forming resistance substance of the host or antibody.
He introduced intramine as a substitute for arsenic compounds
and believed his clinical results were ouch better.

Intramine

contains sulphur, and he believed it less toxic than the
arsenioal compounds and by using this substance with mercury
in form of ool?bined therapy he had his treatment of alternating
reducing and oxidizing agents.
In the days when Ehrlich was making his revolutionary
studies o~ organic arsenical compounds in search of his
"therapia ster111sans magna•, Hata in conjunction with
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Bertheim (5) ~irst showed that when spirochaetes were mixed
with salvarsan, the parasites did not lose their motility
in vitro.

From this, it was concluded that tissue w~s

essential for the therapeutic ef~eot to beoome active.
Bronfennbrenner and Noguchi in 1913 (8) showed that
arsphenamine and neoarsphenam1ne were non-toxic to spirochaetes and trypanosomes in the test tube.

They showed that

neoarsphemmine is broken up by living tissue and the derivatives of neoarsphenamine are especially toxic for spirochaetes.

Experiments with neoarsphenam1ne showed that the

toxicity to spirochaetes was greatly increased by the preeence of living tissue in test tube experiments, but when
this tissue was boiled the toxicity was im.rkedly descreased.
These investigators used liver extract and defibrinated whole
rabbits blood as their experimental tissues.
The first experimental spirochaetal infection to be
treated with an organic arsenical ,compound was hen spirillosis
(3) (Sp. Gallinarum) with atoxyl (Sodium arsanilate) by
Uhlenhuth, Gross and and Bickel in 1907 and these workers
found that si)l?;le doses

of

and ,prophylactically sound.

0.05 gm. per kilo. was both curative
However, atoxyl was found to have

no action in vitro which could Justify its pharmacological
action and this fact in addition to the in vitro action of
salvarsan, et cetera, immediately started speculation as to
the mode o~ action o~ these interesting oompounds.

Levadit1

(9) postulated the mechanism of action of atoxyl as a
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reduction by liver substance and a combimtion o~ t~e reduction product with protein, the latter ,9.oting as the link
~or anchorage to the parasite.

These views of some chemical

change , occurring to the drug being used within the body were
strongly held by many workers, not the least o~ whom was
Ehrlich, who had long before noted that the trivalent
arsenical compounds were DDre toxic both to the -host and to
the paras! te than the pentavalent for ms , am +'ro m these
observations, it was oomluded that oxidation-reduction
reactions took place in the body before the compounds became
therapeutically effective.
It was not until the important work o~ Voegtlin and
Smith 0.0) in 1920, powever, that the nature of the altered
conpound was thought to be known.

These workers showed that ~

the sodium salt _of arsphenamine 1s +'1rst oxidized to the
corresponding oxide and that this compound is simultaneously
oxidized to the pentavalent arsen1cal.

They have shown that

in experimental trypanosom1as1s in rats arsphenamine injections
showed a latent period of +'rom two to t hree hours before the
I

trypanosomes began to disappear from the peripheral blood,
but when arsenoxide or the pentavalent form was administered
in exactly the same man_n er oo such latent period elapsed.
They also found tha t when neoarsphenamine was par tially
oxidized in the air the latent period as described above
was also considerably reduced.

This work seems to show rather
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conolusively that the parasitLcidal action of the arsphenamines is due to conversion in the body of the host of the
drug to a compound of the arsenoxide type.
This work of Voegtlin and Smith received considerable
impetus and confirmation by a subsequent work of Rosenthal (11)
who found that arsenoxide was ten -times nore toxic to organisms

than arsphenamtne and twenty tines nnre toxic than neoarsphenami ne.

Rosenthal developed a color test -ror determining the

presence of arsenoxide by means of napthaquinone and by means
o~ this color test found considerable amount• o~ arsen6~ide
I

in the liver and kidneys of rats following the injection of
arsphenamine an::l neoarsphenam1M, thereby con-rirming the
theory of Voegtlin.
With this theory that the trivalent arsen1oal oompounds
as arsphenamine and neoarsphenamine are oxidized to arseno.xide before the therapeutic effect is apparent, the next
problem at hand was the mechanism where the arsenoxide
compound was therapeutically effective.

It was noted by

Voegtlin, Dyer, and Leonard in 1923 (12) that reduced glutathione and related conpounds counteracted the., action o'f'
arsenoxide compounds on trypanoeomes both in vitro and in the
circulating blood of experimentally infected rats.

This

substance, glutathioM, is a complex protein with a meroaptan
SH radical which has been isolated from liver, muscle and
yeast, and is believed to be an important component of living
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tissue by Voegtl1n (13).

Hopkins and Kem.all (14) have more

recently shown that the SH glutathione is a tripeptide composed o~ cystein, glutam1.c acid and glycine.
Following this discovery that glutathione counteracted
the action of arsenoxide compounds upon spirochaetes and
trypanosomes in vitro and apparently in vivo a mass of work
has been done in an ef'fort to determine just what the action
of this glutathione (if any) is upon the parasites or upon
the drugs in question.

With the work o-r Voegtlin and his

associates in 1923 (12) this work was started and these
workers showed that while the reduced glutathione counteracted the toxie ao•tions o-r the arsenoxide in vitro and in
vivo such compounds as amino acids with no SH group, glucose,
lecithin, and 1oorganio salts did not show this e-r-rect and
these workers therefore concluded that the antitox1c e-r-rect
of SH compounds is due speci-P1cally to the SH group.

These

workers also found that ' trypanosomes as well as all cells
w1 th an active metabolism conta:1nan. SH group probably in glutathione as indicated by a characteristic n1troprusside reaotiDn.
These workers have also postulated that sH compounds injected
intravenously are partly oxidized within the blood and diffuse
in part into the tissues.

In conclusion, they believe that

arsenic in the form o~ arsenoxide R-As» o is a speoi~ic poison
-ror the SH group o-r glutathione and possibly other SH groups
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which occur in protoplasm.
Along this aame line of work Rosenthal working with
Voegtlin (14) showed that rats will easily survive a minimum
lethal dose of arsemxide it they have previously received
an injection of SH glutathion:, in the ratio o~ 10 moles ot
SH glutathione to 1 nnle of arsenic and they have also showed
that a similar protection is af~orded to trypanosomes in
vitro in that if the organisms and arsenoxide are mixed together with sR glutathione the organism lose neither their
motility ·or infeotivity powers.

These workers also believe

that local inflammatory lesions which arise ~rom arsenoxide
1 njeotions are also lost if protection is afforded by the
addition of SH glutathione to the arsenoxide solution prior
to its injection as shown by tests in the ears of rabbits.
These experiments involving the organisms and living
tissues are further oonfirmed· by an exoellant work of
Rosenthal (15) in which he mixed arsenoxide (trivalent arsenical)
with egg albumin, blood serum, ani casein and then ultra
filtered the mixture.
SH groups.

None of these oonpounds contains an

He concluded from these experiments that there was

no conbimtion between the arsenic and these proteins since
the arsenic was present in the filtrate in the same concentration as it was in the mixture.

He also showed that when

the prote+ns were coagulated to bring out the SH groups there
was marked ooni:>1m.t1on between the arsenoxide and the proteins
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which was directly proportiom.l to the concentration o~ the
SH groups as evidenced by the nitroprusside test.

Interestingly

also he showed that ~resh tissue which was supposedly ~ree o~
glutathione but which oontaimd fixed SH groups was shown to
oomb1m with arsenox1de as shown by his ultra~iltration
experiments and he also believed and showed by s~milar experiments that there was no conb1na.tion between the pentavalent
arsenioals and proteins containing the SH group.

In conclus-

ion, he believes that the presence of SH groups gives protection to trypanosomes ~rom arsenical compounds.
These experiments upon the sulf'hydril combination o~
arsenicals have been summarized by Voegtlin and his associates
(16) by their statement o~ the theory that tissue asphyxia and
death results when the

oxidized~ ►

reduced glutathione equil-

ibrium is upset by the addition and combination o~ arsenical
compounds with the SH group o~ this protein.

They also

postulate that the sulfhydril group in tissue mayi well be the
"arseno-receptor" o~ Ehrlich ~or mammalian tissue although
it must be born in mind that there may well .be other arsenoreoeptors than the sul~hydr11 group.
Eagle (17) in a series of in vitro experiments with
experimental syphilis ~ound that oysteine, glutathione, thioglycollio acid and presumably any compound containing a reactive sulfhydril group when added in sufficient excess to
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compounds o~ arsenic, mercury, or bismuth alIIOst completely
abolishes their ant1sp1rooheticidal powers in vitro.

In

connection with this finiing the fact tha t a c~nsiderable
excess o~ the SH substance is necessary suggests that there
may be a hydrolysis o~ the addition reaction product.

The

inportant finding with reference to his work seems to be that
arsenoxide, arsphenamtne, neoarsphenam1ne, mercuric chloride,
and many proprietary bismuth compounds were teste~ and all
proved alike in their action with SH groups.

Thie seems

good evidence for the fact that the chemotherapeutic agents
in syphilis collbine with the SH groups 1n the protoplasm
o~ the Treponema pall1da.

He also showed that th1am1n ~hloride

an:i methionine which conta1 n an -

s-

group but no -

SH group

did not show any such i nhi bi tory action.
SUMMARY

1.

It appears from the evidence as presented that
salvarsan, neosalvarean, et ae t era, are not
directly spirocheticldal as such, since this
cannot be demonstrated in vitro, and the evidence all points to sons change in the compound
within the hunan body before sp irooheticidal
properties are evidenced.

2.

It is now believed that this substance 1s
arsenoxide which is formed from the neosalvarsan
or salvarsan as shown by the work of Voegtlin
and Smith, and e i nee confirmed by aany experiments particularly the work of Rosenthal in
which he demonstrates arsenox1de in the tissues
of' anillBls previously injected with arsphenamine.
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3.

Evidence has been shown that points to the
excellent possibility of the connecting link
between drug and parasite being the meroaptan
sulfhydril radical not only with the organic
arsen1cal compounds, but also with the other
antisyphilitic preparations as mercury and
bismuth.

4.

The evidence points to arsenoxide being
directly toxic to spirochetes rather than
stimulating antibody production or some other
such mechanism.

In conclusion, it may be said that the organic
arsenical preparations exert their action directly upon
the spirochaetes. rather than by antibody stimulation, et
cetera, and that the active principle is probably arsenoxide
or the oxidizidation product o~ salvarsan, et cetera.

The

salvarsan may be oxidized in the body or prior to injection
but it is this arsenox1de which is spirochetloidal.

There

is evidence which points to sulfhydril radicals within the
spiI'l'.JChetes as being the linkage bond with antisyphilitic
drugs; not only the organic arsenicals, but mercury and
bismuth also.

/
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ESSENTIAL PHYSICO-CHEMICAL PROPERTIES OF ARSENICAL
ANTISYPHILITIC AGENTS
The following formulae ~rom Goodman and G1lman•s
text (18) are now given ~or guidance in reading the
following pages:
Alkalinization o~ Arsphenamine
s
NH •HC1
2

HCl•NH20

OH
Arsphenamine hydrochloride
(Arsphene.mine u.s.P.)
+2NaOH

l

0

NHJ)

NH2

OH
Arsphenamine base
+2NaOH
,l,

As

NH2

AS

Q O

NH2

a

ONa

Na Salt of Arsphenamine
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Neoarsphenam1. ne:

As

NH~

.As

00
OH

NH•CH20·SONa

0

Silver Arsphenam1ne:
A

As

(
NH2

ONH2•i-Ag0

"'

ONa

ONa

Sul~arsphenam1ne:

0

A,s==:==As

Naso2 •0•CH2•HN

NH•C112•0•S02Na

iH

OH

0

Bismareen:

0
OH

B1

Naso2 •0•CH 2HN

B1

NHCH 2 •0•S0 Na
2
OH

Mapharsen:

0~

2

OH

D

NHCH 2 • O• so2 Na
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Atoxyl:

(Ehrlich and Bertheim)

oa-o0

11

ONa

NH2

The arsphenam1nes all contain arsenic in the trivalent form and this particular valence seems to be
essential tor their therapeutic action.

The important

feature of the arspbenamine structure is the double bond
linkage between two atoJIB of arsenic as R•As= As•R in which
R is the benzene ring with an amino group attached in the
meta and a hydroxy group in the para position to the
arsenic.

Isomers of arsenic are less spirooheticidal and

it mst be therefore concluded that the ami m and hydroxy
groups are opt1nally placed in the ring for proper physical
and chemical properties in their parasitioidal action.
The arsphe naminee, ·as all chemotherapeutic agents,
owe their action to their physical and chem1.oal properties.
The physical properties nay be classed as colloidal properties, electrical properties, crystalloid properties, et
cetera, while the chemical properties are classed as those
chemical reactions between the compound and tissue constituents.

Arsphenam1nes behave as semi-colloids, since
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the drug dialyses very slowly through parchment and somewhat DX)re rapidly through collodium membranes, and it has
both colloid and crystalloid fractions, (19).

Arsphenamine

base, on account of its basic amino groups and acidic
phenolic grou}'.\ •Y be considered a complex ampholyte whose
conduct is markedly influenced by the pH of the solution
(20).

In view or these ampholytic properties and colloidal

properties of the arsphenam1.nes they may be likened to
proteins and show mny si m1lari ties to prote1 ns.
isoelectric point

or

The

arsphenamine lies in the neighborhood

of blood pH and hence only a small degree

or ionization

takes place at blood pH.
As stated before arsphenam1.ne and its derivatives are
trivalent arsenicals and reduction leads to arsine; oxidation
to trivalent arsenious oxide which in turn can be oxidized
to the pentavalent arsenical as shown by the following
1' or Illllae ( 20)

:

/OH

R•AscQ ~ R•As-0 ~ R•As=:As•R-.;.. R•AsH2
'-oH

(arsenoxide)

(Arsphenam1ne) (arsine)

R represents substituted benzene ring.
None of the arsen1cals used in practice are chemically
pure with the exception of mapharsen or arsenoxide, which
has made biological testing or the oompounds inperative and
it has been shown by Voegtlin that the physical properties
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of the arsphenamines are probably Fespons1ble for the
untoward toxic reactions following intravenous injection,

i.e. the colloidal, protein, and viscosity properties (13).
The colloidal properties are probably the factor in producing the nitritoid crises and shock~like responses and
the pH of the solution probably is also a factor.

In this

respect neoarsphenamine (13) is more dispersed in solution,
only slightly alkaline and readily soluble 1n range of
physiological pH with consequent fewer nitritoid reactions
and anaphlactoid reactions.

Wright (21) and his co-workers

have shown in conjunction with this work that the P.rystallo1d
fraction ls of higher therapeutic index and lower toxic
index than the colloid fraction.
In summarizing the essential chemical properties of
the arsphenamines, we then have:
l.

The arsphenamines all contain trivalent arsenic
which is essential for their therapeutic aotivity.

2.

The arsphenam1nee have great similarity to proteins in being ampholytio and having colloidal
and crystalloid fractions, and it 1s believed
that these physical properties account for many
of the toxic reactions to the host.

3.

The arsphenamines are all readily oxidized both
in vitro and ln vivo, and the role of these
oxidation products in the spiroclleticidal
activity of the drug has been discuss ed at more
length earlier in this paper.

4.

Mapharsen, or arsenoxide, is a ohem1.cally pure
compound thereby not necessitating biological
assay prior to its use.
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EVALUATION OF DRUGS AND METHODS OF THERAPY

With the foregoing in mini, it now rem1ns to be
seen if any log1oal evaluation o~ the therapeutic uses of
the organic arsenicals can be made.

We do krow that

arsphenamines bring about clinical cure and arrests of
syphilis, but we still do mt know any optimum treatment
for all cases.

The reasons for this are many, as stated

by na.ey authors but a few can possibly be enumerated.
(1)

We know very little concerning the characteristics o1"

the etiological agent especially its metabolism, •li1"e
cycle", chemistry, and relatio r:ship to humn tissue.

( 2)

We do not know exactly how our drugs exert their therapeutic effect.

(3)

We have no satisfactory means for

pronouncing a patient cured.

In spite of these drawbacks,

however, we do have e~1"ective means for controlling the
infectiousness of the disease and fairly reliable prophylactic measures.

As stated in the 1 ntroduction to this

paper, our management of syphilis, while it has progressed
amazingly, still lacks a great deal.
as always, has been for an

,tt~~◄Z

The great need, now

d1agnoa1s, followed by a

course o1" treatment which can be terminated in a few days
to weeks with positive assurance to the patient that he 1s
cured.

We now have at our disposal excellent means for

the establishment of early diagnosis but adequate and
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convenient therapy is still lacking.
maey

Because of this,

syphilitics are grossly mismanaged, either because

of inconvenience to the patient, or ignorance on his
part; or because of lack of in-formation or diligence on
the part o-r the physician.

It is the evaluation

ot'

the · · •'

treatment of early syphilis which will now be undertaken
with the idea in mind that what we are really after is

the dream o-r Ehrlich--to cure every syphilitic with from
one to several injections o~ the therapeutic agent and to
kill every spirochaete in the body.
Be-rore the use o-r mapharsen in 1934, the na.jority o-r
early syphilitics were treated with aalvarsan, neoarsphenam1ne, or silver arsphe:ham1ne.

A snall number were treated

with sulpharspherar.l.ne or bismarsen.

The intermittent form

of treatment was used to a large extent with rest periods
during the course of treatment and the araenical drugs
were supplemented with mercury and/or bismuth injections.
In 1931 Cannon and Karelitz (22) reviewed the cases of
436 syphilitics whose histories showed that their disease
was of no more than six months duration before treatment
was started and who remained um.er observation and treatment -ror at least six months.

All of the patients

received supplemental bismuth and/or mercury injections.
The three common ant1syph1lit1cs which they studied were
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salvarsan, neoarsphenami.re, and silver arsphenam1ne.

The

criteria which they based their evaluation upon were:

(1)

time involved in effecting disappearance of the lesions;
(2) reversal of the Wassermann reaction; (3) complications
arising from the administration of the drug, and; (4) the
number of relapses.

After detailed evaluation of the

figures they concluded that salvarsan was superior to both
neoarsphenamine and silver arsphenamine in all respects.
They showed that salvarsan requires fewer injections and
a smaller quantity of the drug to produce the desired

results.

They also showed that a shorter period is

necessary for reversal of the Wassermann reaction with
salvarsan than with the other preparations.

They concluded

that salvarean is the drug of choice and should be used
in spite of technical difficulties encountered in its
administration since its effeot on the patient certainly
warranted its use.
Stokes and Beerman in 1941 (23) gave the following
criteria for the clinical testing of antisyphilitic drugs:
(1) rapidity of surfane spirillicidal antivity; (2) reversal
of serological reactions; (3) low incidence of relapses;
(4) low incidence of central nervous system involvement;
(5) good e~~ect on resistant syphilitic man1~estat1ons and
late syphilis; (6) ultimate curative action, and; (7) low
incidence o~ drug reactiom.

With these criteria in mind
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a great mass of literature has cumulated evaluating all
of the antisyph1litic preparations with the result that

practically the only arsen1cal preparations mw in use
in the treatment o~ early acquired syphilis are salvarsan,
neoarsphenamine, and mapharsen.

»:>st o~ the literature

evaluating these drugs consists of little more than a
tabulation of their toxic reactions to the patient; and
it is ~ot the purpose of this paper to repeat these
tabulations, but rather to see 1f there is any logical
reason for the use of arsenoxide or mapharsen, and
whether the new short term massive dose therapy in early
syphilis is practical.

The results with arsphenamtne and

neoarsphenamine in the treatment of early syphilis with
respect to the above mentiorEd therapeutic criteria are
quite well kmwn to every p1lysioian and will not be
repeated.

In recent years the continuous form of treat-

ment has cone to be accepted as the standard procedure in
early syphilis as compared to the form of treatment used
in the past in which rest periods were believed to be
beneficial. · Excellent evidence to support the continuous
form of treatment is given by Padget (2~), who in 1940 by
a statistical study of 551 patients treated for early
syphilis showed the intermittent form far inferior to the
continuous 'form.

These 551 , patients were followed f'or

from five to ten years after their initial treatment and
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the conclusions were based upon all the criteria for
clinical testing of therapeutic agents as stated earlier.
Padget (24) also believes as many syphilologists, that
the incidence of neurosyphilis is higher am::>ng patients
treated intermittently or inadequately than it is am::>ng
patients who receive oo treatment a_t all.

This evidence

shows plairil.y that th? present trend is for early continuous rigorous treatment without rest periods so as to
hit the spirochaetes hard before they have tine for
entrenchDEnt and multiplication.
Similarly hyperpyrexia has been shown to be inadequate
when used alone in the treatment of early acute syphilis.
Boak and her co-workers (25) in 1942 gave eight patients with
primary and secondary syphilis from nine to fifteen hours
of artificial fever at from 41.0

0

C, to 41,5° C,

There was

prompt resolution of the early lesions in all cases, but in
four out of five patients who received no chemotherapy whatsoever there were mucooutaneous relapses and the fifth
patient continued to have positive serology, but no obvious
infectious relapse.

She therefore aoneludea, as does Leifer

(26), that hyperpyrexia alone is not suitable in the treatment of early syphilis because human tissue cannot tolerate
the thermal death point of the treponema pallida.
With these seemingly well established pr1no1ples in

mind.; namely, early treatment is essential, treatment must
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be continuous and rigorous, and chemotherapy is essential
for proper treatment, we oan now proceed to attempt to
evaluate the best pos s ible means for treating early
acquired syphilis.

As has been stated earlier the evid-

ence points to an arsenoxide compound being the active
antispiroohetal agent, and salvarsan and neosalvarsan are
not directly spirochetioidal.

We now have at our disposal

arsenoxide or 1119.pharsen which has been used clincially and
evaluated in the literature as much as possible.

Tatum and

Cooper (27), in a study of forty-~our cases of experimental
rabbit s yphilis treated with mapharsen showed that mapharsen
has certain definite advantages over salvarsan and neoarsphenamine.

They state that mapharsen is a chemically

pure compound reoquiring no biological assay as arephenamine;
it

1s less toxic upon oxidation than arsphenamines; the

therapeutic dose is from l/50th to l/30th that of neoarsphenamine; the therapeutic index is greater than for the
arsphenam1nes; and the preparation may be ampouled with
Naco3 and NaCl ~or neutralization and isotonicity.

Leifer

(26) in a cl1nc1al study of one hundred and eighty early
cases treated with mapharsen and one hundred and eighty
early cases treat ed with neoarsphenamine showed that the
percentage of

11

with mapharsen.

cunes" was about equal or slightly greater
However, the number of reactions were mu~,h

less with mapharsen tha.n with neoarsphenami ne and there were
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no n1tr1toid reactions with mapharsen.

Stokes and Beerman

(23) in an evaluation of mapharsen have shown that the drug
1s rapidly sp1rillicldal and e~fectively heals lesions.
The drug also gives an early reversal o~ serology and good
symptomatic response.

Naturally the big question at present

concerning mapharsen is whether or oot its apparently
e.xoellent effects will be permanent.

Stokes and Beerman,

however, believe that any deficiencies in this respect
will be compensated for by heavy metal therapy.
From a theoretical standpoint mapharsen seems to be
the drug of choice in the treatment of early syphilis.

This

conclusion:· is arrived at from the fact that the evidence
points to 1 ts .- being act1 vely spirooheticidal and also beoau se
it is easy to administer and has a relative lack of toxicity.
Naturally 1 ts staying power from a thera.peut1o standpoint
cannot be very well evaluated as yet.

This theoretical

viewpoint is born out by ol1n1cal evidence as outlined above.
In 1935 and again ln 1939 Cha.rgin, Leifer and Hyman (28)
described the treatment and olintcal cure of early syphilis
with five day intravenous continuous drip methods for twelve
hours daily.

They first used salvarsan and neoarsphenamine

I

but these drugs were soon discarded because of central
nervous system damage and peripheral neun1t1s.
Since that tine a large number o~ patients have been
treated by this method and also by massive doses over a
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slightly longer period with or without hyperpyrexia.
Following the abandonment o~ arsphenam1ne and neoarsphens.mi ne in massive dose therapy, mapharsen has been used.
The usual dosage is from 80 to 240 mg. daily with a total
dosage of about 1200 mg. (28)

This is the average amount

used either with contiruous drip or massive syringe method
regard.less of whether or not hyperpyrexia is used in
conjunction.
. The ~ollow1ng chart (29) is a compilation of recent
reports on massive dose arsenother-a py.

,0 ~D.

(r J

SUMMARY OF RECENT REPORTS
ON

MASSIVE DOSE ARSENOTHERAPY

.f
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Failures
inolud1ng
possible

.

n.e ac 1, 1. o ns

~

Toxic enceph- Toxioo- Peripheral Exf'oliat1ve
alopathy
derma
neuritie dermatitis

•

Jaundioe

rein'feotinn
6

2

24

50
35

39

3

5

1
0

8

--

-·

--

--

---

11~

--

0

2

--

0

0

--

--

--

--

---

---

2

2

5 to 15~

8

2

---

--

1~

1

---

--

4

2

..... .
~

No serious reac tions

--

--

No serious reactions

0

8

l

5

--

l

--

---

l

60

4

--

'

?

l

5

4

?
8

2

3

0

?

18

1.
2.

7

---

2
1

0

l

Arsehosan-- A hydrochloride of' metas.m1nopai,ahydroxyphenylars1ne similar to mapharsen.
Ox1arsolan--Arsenox1de hydrochloride.

7
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No. of' Arsenical
Patients Administered

Author

Method Total Duration Deaths
Dose
(days)
(mg. )

Berry

50

mapharsen

I.V. Drip 1200

5

0

Usher and
Hill

36

mapharsen

I.V. Drip 1200

5

0

270

mapharsen

I.V. Drip

10

1

3

0

Brun,Ramirez
and Roman
'

Prunes and
Hevia

360

to

.d..d.n

60

neo

I.V. Drip
and one
5400
injection
one week
later

to
7

I

~

- 38 - - - - - - - - - - Reactions - - - - - - - - - - - -Failures
1nalud1ng
possible
T-A1

Toxic enC"eph- Tox1co- Peripheral Ex1'ol1at1ve Jaundice
alop&thy
derma
neun1t1s dermatitis

ni"e~ti nn

l

n

1

0

0

1

2

l

5

3

0

0

1

0

15%
--

--

3.5~

--

---

--

--

-

2 to 4%

--

-.--

-

--

-

1

'

--

-

---

Summarization o'f Mapharsen Treatment
Total cases • • • • • • • • • . 3300
Failures • • . . . . . . . . . . 291 - ,8.fffo a'f.,-total
Deaths. • • . • . • . • • • - -; • .12 -o. 36%, of' "'to tal
Reactions • • . . . . . . . . . 400 -12.1%, o'f total
Tox1coderma • • . • • . . . 291
Peripheral neuritis . • - ; . . 72
Ennephalopathy • • • • . • • 15
Ex'fol1at1ve dermatitis . . . 2
Jaundice . . . . . . • • • . 15
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From a summarization of the preceding chart, it 1s at
once apparent that the toxic effects of neoarsphenamine are
prohibitive of 1 ts use with this method.

In the oa.se of

mapharsen, however, the results are considerably better.
A sample of 3300 cases seems sufficient for some fairly
definite statements.

The percentage o~ deaths (0.36%) and

the percentage of serious toxic reactions (12.1%) are both
too high for conservative therapeutic standards.

However,

the number of failures, including possible reinfections
(8.8%), is very encouraging although naturally this figure
is open to dispute since sufficient tine has not elapsed
in ma?)' instanoes for proper evaluation of the curative
powers of' the procedure. · :To summarize, we· may then say that a shorter, more
intensive form of therapy 1s needed sime our present long
term therapy is not suited for proper treatment of all
patients and the evidence points to conti ruous rigorous
treatment being the method of choice in early syphilis.
Mapharsen see ms to be the theoretical drug of' choic·e and
this is born out to a certain extent by clinical evidence
although the preparation is too new for a complete evaluation therapeutically.

l4a.ssive arsenotherapy is theor-

etically sound and a step toward the ideal treatment
although at present it must be considered in the experimental stages.
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CONCLUSIONS
1.

The evidence at present is that the arsphenamines

exert the~r spirochetioidal properties only a.~ter oxidation;
and the oxidation product ls directly spirochet1c1dal.

The

sp1rochetic1dal agent is believed to be arsenoxide and
there is evidence which points to sulfhydr11 groups in the
protoplasm o~ the Treponema pallida being the "chemoreoeptor"
between drug and parasite.
2.

At the present tine, the theoretical drug o~ choice

in the treatment o~ early syphilis seems to be mapharsen
or arsenoxide.

This opinion is advanced in view of the fact

that the evidence points to its being the active sp1rocheticidal agent.

Also the drug is relatively non-toxic, is

easy to administer, and ls a ohemioally pure compound not
requiring biological assay.
3.

The evidence points to the uee o~ contiruous rigor-

ous, massive doses o~ the therapeutic agent as the method
o~ choice in the treatment o~ early syphilis.
4.

Arsenoxide apparently acts directly on the

apirochaetes and its toxic action upon the spirochaetes is
rel a tively quick.

It therefore seems that i~ ways and

means of getting a sufficient concentration o~ the drug
into the body for its sterilization can be attained, we
will have answered the question of the ideal treatment of
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early syphilis.

At present, however, we have not found

these means since the drug is too toxic to the patient
when used in these concentrations.

The new methods of

massive arsenotherapy are a step in this direction, however,
but at present they must be considered in the experimental
stages because of' technical di f'f'ioul ties lil1<l the high
mortality and morbidity associated with their use.
5.

The method of' choioe for all but the expert in

the treatment of' ~arly syphilis at the present tine is a
'form of' co nti ruous arsenical and bismuth injeotions over a
period of' months to years as outlined in all texts ·on the
treatment of syphilis.
6.

There ls a great need 'for more kmwledge o-r the

physico chemical relationships between the drugs and
parasites and between the drugs and tissues since herein
lies the secret of producing the therapeutic agent which
will chemically combine with the protoplasm of the parasite
~1th a toxic result, but whicll will not tox1oally oonbine
with the tissues of' the host.
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